Literature DB >> 23007193

Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

Ashok Sriram1, Herbert E Ward, Anhar Hassan, Sanjay Iyer, Kelly D Foote, Ramon L Rodriguez, Nikolaus R McFarland, Michael S Okun.   

Abstract

It has been previously well established that the use of dopaminergic agents in Parkinson's disease may contribute to behavioral disturbances such as dopamine dysregulation syndrome (DDS), impulse control disorders (ICD), and punding. ICD and punding have been most commonly addressed by reducing dose or by discontinuing the use of a dopamine agonist. Treatment of DDS has proven more challenging, and to date there has been no standard approach. In this paper, we review a series of four patients who met criteria for DDS, who were all refractory to medication adjustments. The DDS symptoms responded by the addition of valproic acid in all cases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007193     DOI: 10.1007/s00415-012-6669-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

1.  The anticonvulsant response to valproate in kindled rats is correlated with its effect on neuronal firing in the substantia nigra pars reticulata: a new mechanism of pharmacoresistance.

Authors:  Kathrin Töllner; Saskia Wolf; Wolfgang Löscher; Manuela Gernert
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

2.  Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture.

Authors:  M J McLean; R L Macdonald
Journal:  J Pharmacol Exp Ther       Date:  1986-06       Impact factor: 4.030

3.  Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times.

Authors:  Ying Jiao Zhao; Hwee Lin Wee; Yiong-Huak Chan; Soo Hoon Seah; Wing Lok Au; Puay Ngoh Lau; Emmanuel Camara Pica; Shu Chuen Li; Nan Luo; Louis C S Tan
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

4.  Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA.

Authors:  W Löscher
Journal:  J Neurochem       Date:  1980-06       Impact factor: 5.372

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 6.  Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?

Authors:  Andrew D Lawrence; Andrew H Evans; Andrew J Lees
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

Review 7.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.

Authors:  Daniel Eikel; Alfonso Lampen; Heinz Nau
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

Review 9.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  Andrew H Evans; Antonio P Strafella; Daniel Weintraub; Mark Stacy
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

10.  Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome.

Authors:  Sarah J Moum; Catherine C Price; Natlada Limotai; Genko Oyama; Herbert Ward; Charles Jacobson; Kelly D Foote; Michael S Okun
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

View more
  6 in total

Review 1.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 2.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

Review 3.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  Drug-Induced Mitochondrial Toxicity.

Authors:  Iain P Hargreaves; Mesfer Al Shahrani; Luke Wainwright; Simon J R Heales
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

Review 5.  Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review.

Authors:  Domenico Pirritano; Massimiliano Plastino; Domenico Bosco; Luca Gallelli; Antonio Siniscalchi; Giovambattista De Sarro
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

Review 6.  Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies.

Authors:  Jun-Fang Zhang; Xi-Xi Wang; Ya Feng; Robert Fekete; Joseph Jankovic; Yun-Cheng Wu
Journal:  Front Psychiatry       Date:  2021-02-09       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.